CHIRHOSTIM SUMMARY
Human secretin is a gastrointestinal peptide hormone produced by cells in the duodenum in response to acidification. ChiRhoStim® (human secretin as the acetate) is a purified synthetic peptide with an amino acid sequence identical to the naturally occurring hormone.
ChiRhoStim® is indicated for:
Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction,
Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma, and
Facilitation of the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP).
|
NEWS HIGHLIGHTS
Published Studies Related to Chirhostim (Secretin)
Intravenous synthetic secretin reduces the incidence of pancreatitis induced by endoscopic retrograde cholangiopancreatography. [2011.05]
OBJECTIVES: This study aimed to evaluate whether synthetic secretin is effective in reducing post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis... CONCLUSIONS: Synthetic secretin reduces the risk of post-ERCP pancreatitis, particularly in patients in undergoing biliary sphincterotomy.
Effects of early enteral feeding on fecal elastase 1 and plasma secretin. [2010.08]
BACKGROUND: Enteral feeding is known to be effective on the development of gut hormone secretion and pancreatic exocrine function. The aim of the present study was to examine the effects of extremely early enteral feedings on the development in very low-birthweight (VLBW) infants... CONCLUSIONS: Extremely early enteral feedings may play an important role in the development of pancreatic exocrine function and secretin secretion in the early period of life in VLBW infants. (c) 2010 Japan Pediatric Society.
Secretin effects on cerebellar-dependent motor learning in schizophrenia. [2009.04]
CONCLUSION: If cerebellar abnormalities in individuals with schizophrenia are associated with fundamental mechanisms and symptoms of the disorder, as suggested by the cognitive dysmetria model, then cerebellar-targeted treatments may provide a novel approach to treatment for schizophrenia.
A prospective crossover study comparing secretin-stimulated endoscopic and Dreiling tube pancreatic function testing in patients evaluated for chronic pancreatitis. [2008.03]
BACKGROUND: Direct pancreatic function tests (PFT) are conventionally performed with use of double-lumen "Dreiling" collection tubes. We have developed an endoscopic collection method (ePFT) that eases the performance of these tests. OBJECTIVE: Our aim was to compare the bicarbonate results obtained from the secretin ePFT and Dreiling PFT methods in patients evaluated for chronic pancreatitis... CONCLUSION: The secretin ePFT yields results similar to those of the Dreiling PFT in patients evaluated for chronic pancreatitis.
Evaluation of somatostatin inhibitory effect on pancreatic exocrine function using secretin-enhanced dynamic magnetic resonance cholangiopancreatography: a crossover, randomized, double blind, placebo-controlled study. [2006.05]
OBJECTIVES: Somatostatin inhibitory effect on the exocrine pancreas has been demonstrated by clinical and experimental studies performed with invasive investigative methods. The aim of this study was to quantify the inhibitory effect of low doses of somatostatin (62.5, 125, and 250 microg) on secretin-stimulated pancreatic exocrine secretions using magnetic resonance cholangiopancreatography (MRCP)... CONCLUSIONS: Low doses of somatostatin inhibit pancreatic exocrine secretions as demonstrated noninvasively with MRCP.
Clinical Trials Related to Chirhostim (Secretin)
Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma [Not yet recruiting]
Secretin Infusion for Pain Due to Chronic Pancreatitis [Recruiting]
- To determine if intravenous secretin administration in escalating doses three times
daily for three days will improve the pain from CP at the time of infusion, after each
infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
- To validate the safety of intravenous secretin administration at the dosage indicated
in this study.
Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency [Not yet recruiting]
The aim of our study is to evaluate S-MRCP, in comparison to direct pancreatic function, to
measure pancreatic exocrine function in patients who have symptoms suspicious for
insufficiency. We hypothesize that S-MRCP imaging parameters will correlate well with the
direct pancreatic exocrine functioning.
Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery [Not yet recruiting]
The aim of this study will be to determine whether secretin-enhanced MRCP (S-MRCP) as well
as traditional magnetic resonance imaging (MRI) of the pancreas will allow the investigators
to quantify the pancreas' ability to secrete hormones as well as digestive enzymes, both
before and after surgery. The investigators hypothesize that S-MRCP will provide a novel
non-invasive measure of pancreatic function.
Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) as Screening in Familial Pancreatic Cancer (CA) Patients [Recruiting]
The aim of our study is to evaluate the utility of S-MRCP in detecting carcinoma and
precancerous lesions in patients with a significant family history of pancreatic
adenocarcinoma. Our hypothesis is that S-MRCP is superior to traditional computed tomography
(CT) or magnetic resonance imaging (MRI) in detecting early pancreatic neoplasms, and
approaches the accuracy of endoscopic ultrasound (EUS).
|
